Memo Therapeutics

What Memo Therapeutics does

Memo Therapeutics AG is a privately held Swiss biotechnology company headquartered in Schlieren (Zurich), founded in 2014 by Christoph Esslinger. The company develops therapeutic antibodies derived from natural immune responses in elite responders to viral infections and cancer, using its proprietary DROPZYLLA® platform — a microfluidic single-cell engine that copies antibody genetic information from human B cells into immortal cell lines, achieving greater than 80% immune repertoire coverage compared to under 1% for conventional approaches.

Its lead asset, potravitug, is a highly potent human BK polyomavirus (BKPyV)-neutralizing monoclonal antibody in Phase II/III development for treatment of BKPyV infection in kidney transplant recipients, a population of approximately 20% of transplant patients within one year and up to 50% over the lifetime of the transplanted kidney, with no approved disease-modifying therapy. Potravitug has received FDA Fast Track designation (May 2023) and EU Orphan Drug Designation (December 2025). The Phase II SAFE KIDNEY II trial enrolled 95 patients across 22 U.S. sites, with complete data presented at the American Transplant Congress in June 2026 and pivotal Phase III initiation planned for 2026.

The company operates a secondary oncology program mining tumor-infiltrating B-cell repertoires from elite cancer responders, with a discovery collaboration with Ono Pharmaceutical, and a recombinant polyclonal IgG platform partnered with CSL in a deal announced February 2026 with up to CHF 265 million in potential milestones plus single-digit royalties. Memo Therapeutics is pre-commercial, generating no product revenue; its income is limited to R&D funding, technology access fees, and contingent milestone payments from partners. Capital is sourced from a venture-backed investor base including Pureos Bioventures, Ysios Capital, Kurma Partners, Swisscanto, Vesalius Biocapital, and Adjuvant Capital, with cumulative Series C funding of approximately CHF 46 million and a leadership team being deliberately expanded with senior commercial and clinical operations executives ahead of Phase III readiness.

Name

Memo Therapeutics

Legal name

Memo Therapeutics AG

Website

https://memo-therapeutics.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

Memo Therapeutics AG is a Swiss biotech developing therapeutic antibodies from elite human immune responders using its proprietary DROPZYLLA® single-cell platform, with lead asset potravitug in Phase II/III for BK polyomavirus infection in kidney transplant recipients and additional programs in oncology and recombinant polyclonal IgG.

Ownership category

akta.pro rank

Product category

Therapeutic Antibodies

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

Keywords

• Therapeutic antibody discovery
• Monoclonal antibody development
• Immune repertoire analysis
• BKPyV antiviral therapeutics
• Immuno-oncology antibodies

Headquarters

HQ city

Schlieren

HQ country

Switzerland

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Others

Revenue model

1. Pharmaceutical Product Sales: Revenue from commercialization of therapeutic antibody products upon regulatory approval. Lead product potravitug targets BKPyV infection in kidney transplant recipients with market potential of up to $2 billion annually.
2. Licensing and Milestone Payments: Collaboration with CSL includes R&D funding, technology access fees, and development/sales milestones up to CHF 265 million (USD 328 million) plus single-digit royalties assuming option exercise.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Memo Therapeutics AG develops best-in-class therapeutic antibodies derived from natural immunity in elite responders to viral infections and cancer. The lead program is potravitug, a BK polyomavirus-neutralizing monoclonal antibody for treating BKPyV infection in kidney transplant recipients (Phase II/III). The company also operates an oncology program mining tumor-infiltrating B-cell repertoires, a Recombinant Polyclonal IgG Technology platform, and previously developed MTX-COVAB for COVID-19. Underpinning the portfolio is the proprietary DROPZYLLA® microfluidic single-cell antibody discovery platform.

Product overview

Memo Therapeutics AG is a late-stage biotech company developing best-in-class therapeutic antibodies based on natural immunity in elite responders to treat viral infections and cancer. The company's lead product is potravitug, a BK polyomavirus-neutralizing monoclonal antibody for kidney transplant recipients, currently in Phase II/III development. Underpinning the portfolio is the proprietary DROPZYLLA® technology platform, a high-throughput microfluidic single-cell antibody discovery system. The company also operates an oncology program developing antibodies from tumor-infiltrating B-cells, a recombinant polyclonal IgG technology platform, and previously developed MTX-COVAB for COVID-19. The company has partnerships with CSL for recombinant polyclonal IgG development and Ono Pharmaceutical for oncology antibody discovery.

Differentiator

Problem solved

Functional benefit

Products and services

• Potravitug (AntiBKV) A highly potent human BK polyomavirus (BKPyV)-neutralizing monoclonal antibody that binds to the VP1 capsid protein and blocks viral attachment to target cells. Developed for treating BKPyV infection in adult kidney transplant recipients, where it has demonstrated sustained reduction in viral load and biopsy-proven resolution of BKPyV-associated nephropathy. In Phase II/III development with FDA Fast Track and EU Orphan Drug designations.
• DROPZYLLA® Antibody Discovery Platform Proprietary microfluidic-based single-cell antibody repertoire copying engine that extracts antibody genetic information from B cells and copies it into robust immortal cells for screening. Creates near-complete human antibody repertoires (greater than 80% coverage versus less than 1% for conventional approaches) and enables iterative high-throughput functional screening of recombinant antibody libraries for viral infections and cancer. Licensed for partnership use, including under the CSL collaboration.
• Oncology Program (Tumor-Infiltrating B-cell Antibody Discovery)

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Six partnerships are on record, tiered core, secondary and supporting.

• CSLcoreOEM/ Whitelabel/ Licensing Partner · 9 February 2026Strategic collaboration and exclusive option-to-license agreement for development of recombinant polyclonal IgG technology using proprietary DROPZYLLA® platform. MTx will develop recombinant polyclonal IgG products receiving R&D funding, technology access fees, and assuming option exercise, milestones and license fees totalling up to CHF 265 million (USD 328 million) plus single-digit royalties. Collaboration combines CSL's global leadership in immunoglobulins with MTx's recombinant polyclonal technology.
• Ono PharmaceuticalsecondaryStrategic or Co-development PartnerCollaboration to use DROPZYLLA® technology to discover antibodies for immuno-oncology targets. Pharma partners value MTx's ability to move projects quickly and get results fast, with ability to see project development in real time.
• Vakzine Project Management GmbH (VPM)supportingImplementation/ SI/ Consulting PartnerBased in Hannover, Germany, responsible for translational project management and clinical trial oversight.
• Accelagen Pty LtdsupportingImplementation/ SI/ Consulting PartnerBased in Melbourne, Australia, responsible for clinical trial management.
• TFS HealthSciencesupportingImplementation/ SI/ Consulting PartnerHeadquartered in Lund, Sweden with subsidiaries in Europe and North America. Responsible for clinical trial management.
• Northwestern UniversitysupportingStrategic or Co-development PartnerResearch partnership for qualitative study on impact of BK polyomavirus on health-related quality of life in kidney transplant recipients. Published in Journal of Patient-Reported Outcomes.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Market position

Strengths4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/memo-therapeutics-ag

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries1 record

Funding overview

Funding rounds7 records

Investors18 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Memo Therapeutics